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Mortality and morbidity in patients with ST elevation myocardial
infarction (STEMI) treated with primary percutaneous coronary inter-
vention (PCI) are still high [1]. A huge amount of the myocardial
damage is related to the mitochondrial events happening during
reperfusion [2]. Several drugs directly and indirectly targeting mito-
chondria have been administered at the time of the PCI and their effect
on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal
(hospital readmission for heart failure (HF)) outcomes have been tes-
ted showing conﬂicting results [3–16]. Data from 15 trials have been
pooled with the aim to analyze the effect of drug administration
versus placebo on outcome [17]. Subgroup analysis are here analyzed:
considering only randomized clinical trial (RCT) on cyclosporine or
nicorandil [3–5,9–11], excluding a trial on metoprolol [12] and com-
paring trial with follow-up length o12 months versus those with
longer follow-up [3–16]. This article describes data related article titled
“Clinical Beneﬁt of Drugs Targeting Mitochondrial Function as an
Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction:
a Meta-Analysis of Randomized Clinical Trials” [17].
& 2017 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Clinical research; meta-analysis
ore speciﬁc
subject areaMedicine; Cardiology; Reperfusion injuryype of data Figure
ow data was
acquiredMeta-analysisata format Analyzed
xperimental
factorsCiclosporin or nicorandil, exclusion of metoprolol and follow-up length for reperfusion
in ST elevation myocardial elevation treated with primary coronary intervention.xperimental
features15 studies focused on drugs targeting mitochondrial function vs. placebo in
patients undergoing primary PCI for STEMI, of which 3 with cyclosporine, 2 with
nicorandil, only one study with metoprolol were retrieved from MEDLINE,
Cochrane Library, Google Scholar and Biomed Centralata source
locationItaly, USA, Israel, Japan, Denmark, UK, France, Norway, Spain.ata accessibility Data is with this articleDzienda Ospedaliera Universitaria S. Anna, Via Aldo Moro 8, 44124 Cona,
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 The use of cyclosporine or nicorandil at the time of primary percutaneous coronary angioplasty
(PCI) on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission
for heart failure (HF)) outcomes, show the absence of any potential beneﬁt.
 Excluding a trial on metoprolol [12], which has a complex mechanism of action, not targeting only
mitochondrial function, the pooled analysis on fatal and non fatal outcomes of the 14 studies did
not changed.
 The analysis on follow-up length shows effects on hospital readmission for HF for trials with longer
follow-up.
 These additional analyses should be the basis to plan further randomized clinical trials (RCTs) on
reperfusion injury in ST elevation myocardial infarction (STEMI) patients undergoing PCI, focusing
attention on other molecular mitochondrial targets.
 New RCTs on reperfusion injury should have a longer follow-up analysis.1. Data
Considering only trial focused on cyclosporine versus placebo, the HR for CV mortality, all-cause
mortality and hospital readmission for HF were not statistical signiﬁcant (p¼0.33; p¼0.16; p¼0.95,
respectively) (Fig. 1). The same data are obtained considering only trials on nicorandil (p¼0.06 for CV
mortality; p¼0.07 for all-cause death; p¼0.2 for hospital readmission for HF) (Fig. 2). After the
exclusion of the study on metoprolol from pooled analysis on trials with indirect/unspeciﬁc
mechanism of action against mitochondrial component/pathway, the HR for CV death, all-cause death
and hospital readmission for HF were signiﬁcantly reduced (p¼0.03; p¼0.008; p¼0.0001, respec-
tively) (Fig. 3). Finally, the analysis on follow-up on all the studies included in the meta-analysis
showed a reduction in hospital readmission for HF in studies with follow-up length Z12 months (HR
0.46; 95% CI 0.45–0.92, p¼0.03) (Figs. 4–6).2. Experimental design, materials and methods
2.1. Search strategy
A systematic review and meta-analysis was performed following Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) criteria [18–21]. The protocol of this study was
published on PROSPERO (CRD42016033085).
Papers were retrieved in MEDLINE, Cochrane Library, Google Scholar and Biomed Central. The
terms searched were: (reperfusion injury) AND ((PCI) OR (percutaneous coronary intervention) OR
(ST elevation myocardial infarction) OR (STEMI) OR (myocardial infarction)) [3–16].
2.2. Selection criteria
Detailed description of selection criteria of the papers is described elsewhere [17]. In particular, we
focused on i) RCTs ii) enrolling STEMI patients; with iii) reperfusion strategy by primary PCI; iv)
comparison of agent/drug against RI vs. placebo/gold standard treatment.
2.3. Data abstraction, endpoints, contact with authors
We performed a pre-hoc stratiﬁcation of studies according to mechanism of action targeting a
mitochondrial component/pathway (direct/selective vs. indirect/unspeciﬁc) according to a recent
overview [22]. The analyses were performed according to the following criteria: i) administration of
cyclosporine, ii) administration of nicorandil, iii) follow-up length o12 vs. Z12 months iv) indirect/
unspeciﬁc drugs after exclusion of the study of Pizarro et al. [12]. The primary endpoint of the analysis
Fig. 1. Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing to
cyclosporine vs. placebo. CV: cardiovascular.
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readmission for heart failure (HF).2.4. Data analysis and synthesis
The endpoints were expressed as odds ratio (OR). Point estimates and standard errors were cal-
culated and combined by the generic inverse variance method [23], computing risk estimates with
95% conﬁdence intervals according to logarithmic transformation of the OR. A random effect model
was used. Statistical heterogeneity was assessed with the Cochran's Q test and the I2 statistic [24]. To
test the difference between sub-group analyses the Chi2 test has been used. Prometa (Internovi,
Cesena, Italy) and RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen,
Denmark) software were used for statistical analyses.
Fig. 2. Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing to
nicorandil vs. placebo. CV: cardiovascular.
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Fig. 3. Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing
indirect/unspeciﬁc mechanism of action against mitochondrial component/pathway vs. placebo, excluding the study on
metoprolol [12]. ANP: atrial natriuretic peptide. NIC: nicorandil. CV: cardiovascular. HF: heart failure. hosp: hospitalization.
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Fig. 4. Forest plot on cardiovascular mortality after stratiﬁcation of studies according to follow-up length. SP: safety population.
ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil. CV: cardiovascular.
Fig. 5. Forest plot on all-cause mortality after stratiﬁcation of studies according follow-up length. SP: safety population. ANT:
anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil.
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Fig. 6. Forest plot on hospital readmission for heart failure after stratiﬁcation of studies according follow-up length. SP: safety
population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil. HF: heart failure.
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